Thomson Reuters announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development. Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters. Financial terms of the transaction were not disclosed.

The acquisition enables Thomson Reuters to provide the pharmaceutical, biotechnology, and academic research communities with solutions that provide better understanding of the underlying mechanism of disease and potential therapies. GeneGo's scientific expertise and assets in biology-driven drug discovery complement the Thomson Reuters life sciences portfolio that covers drug pipeline competitive intelligence, patents, and chemistry.

“Thomson Reuters now provides comprehensive decision support solutions to help researchers striving to bring more effective medications to market,” said Jon Brett-Harris, executive vice president at Thomson Reuters. “There is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalized approach to medicine.”

GeneGo's capabilities include: MetaBase, a comprehensive and respected knowledge base in systems biology. Expertise in analytics, data management, and value-added services. An experienced management team and a skilled scientific staff. A successful track record deploying decision support systems.

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. Thomson combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks.